Document is current
Any future updates will be listed below
-
Authors
Nimri, Revital http://orcid.org/0000-0003-3571-4938
Battelino, Tadej http://orcid.org/0000-0002-0273-4732
Laffel, Lori M.
Slover, Robert H.
Schatz, Desmond
Weinzimer, Stuart A. http://orcid.org/0000-0002-7768-5189
Dovc, Klemen http://orcid.org/0000-0001-9201-2145
Danne, Thomas
Phillip, Moshe http://orcid.org/0000-0002-6616-5612
,
Phillip, Moshe
Nimri, Revital
Shalitin, Shlomit
Bello, Rachel
Nevo-Shenker, Michal
Fisch-Shvalb, Naama
Shiovitch-Mantzuri, Galit
Choresh, Orit
Drutz, Irit
Nava, Yehiel
Hemo, Alona
Hermon, Orna
Nave, Rachel
Battelino, Tadej
Dovc, Klemen
Bratina, Natasa
Smigoe-Schweiger, Darja
Mali, Brigita
Gianini, Ana
Sever, Urska
Berkopec, Barbara Murn
Laffel, Lori M.
Katz, Michelle
Isganaitis, Elvira
Mehta, Sanjeev
Quinn, Heidi
Naik, Nisha
Guo, Zijing
Volkening, Lisa
Slover, Robert H.
Forlenza, Gregory
Wadwa, R. Paul
Alonso, G. Todd
Messer, Laurel
Towers, Lindsey
Thivener, Katie
Berget, Cari
Lange, Samantha
Jost, Emily
Rossick-Solis, Maria
Schatz, Desmond
Haller, Michael
Hiers, Paul
Jacobsen, Laura
Smith, Madison
O’Neill, Anastasia
Hosford, Jennifer
Perry, Alexis
Weinzimer, Stuart A.
Cengiz, Eda
Sherr, Jennifer
Gibbons, Kathryn
Carria, Lori
Zgorski, Melinda
Danne, Thomas
Biester, Torben
Kordonouri, Olga
von dem Berge, Thekla
Biester, Sarah
Remus, Kerstin
-
Funding
Funding for this research was provided by:
The Leona M. and Harry B. Helmsley Charitable Trust
- License Information
-
More Information
Article History
Received: 3 March 2020
Accepted: 3 August 2020
First Online: 9 September 2020
Competing interests
: R.N. reports receiving grants from Helmsley Charitable Trust, Dexcom and Insulet, personal fees and others from DreaMed Diabetes Ltd, personal fees from Novo Nordisk and Eli Lilly and grants from Medtronic. In addition, R.N. owns DreaMed Diabetes Ltd stock and has a patent licensed by DreaMed Diabetes Ltd. T.B. reports receiving grants and personal fees from Novo Nordisk, Medtronic and Abbott, personal fees from Eli Lilly, Sanofi, Indigo, Roche, AstraZeneca and Dexcom and grants from Glusense and Zealandpharma. In addition, T.B. owns DreaMed Diabetes Ltd stocks. L.M.L. reports receiving grants from Helmsley Charitable Trust and personal fees from Eli Lilly, Novo Nordisk, Sanofi, Convatec, Roche, Insulogic, Dexcom, Insulet, AstraZeneca, Boehringer Ingelheim and Janssen. S.A.W. reports receiving grants from Helmsley Charitable Trust, grants and personal fees from Medtronic and personal fees from Insulet, Tandem, Eli Lilly, Sanofi and Zealand. T.D. reports receiving grants and personal fees from AstraZeneca, DexCom, Boehringer, Novo Nordisk, Medtronic, Sanofi, Eli Lilly and Insulet. In addition, T.D. owns DreaMed Diabetes Ltd stocks. M.P. reports receiving grants from Helmsley Charitable Trust, Dexcom and Insulet, personal fees and others from DreaMed Diabetes Ltd, grants and personal fees from Medtronic and Novo Nordisk, grants from Roche, Eli Lilly and Sanof, grants from Lexicon and OPKO and personal fees from RSP Systems and Qulab Medical. In addition, M.P. owns DreaMed Diabetes Ltd stock and has a patent licensed by DreaMed Diabetes Ltd. R.H.S., D.S. and K.D. declare no competing interests.
